Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$48.00 USD
+0.69 (1.46%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $47.96 -0.04 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
IONS 48.00 +0.69(1.46%)
Will IONS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Other News for IONS
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Ionis Pharmaceuticals price target raised by $3 at Stifel, here's why
Ionis Pharmaceuticals: A Strong Buy on Regulatory Milestones and Pipeline Progress
Ionis Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for IONS